Jiangsu Hengrui Pharmaceuticals Co Ltd
-
Hengrui’s Class 1 Drug for Psoriasis Treatment gets clinical trials approval
Mar, 2024.4 According to the CDE official website, Hengrui Pharmaceuticals’ clinical trial application for Class 1 new drug SHR-1139 injection has received implicit permission, and the indication is psoriasis.
-
Retagliptin Phosphate Tablets approved by China NMPA for type 2 diabetes
Jun,2023. Retagliptin Phosphate Tablets, the Class 1. New drug from Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of type 2 diabetes, is approved by China NMPA.
